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Abstract
Background: Numerous studies have demonstrated that the NDV-mediated gene therapy is a promising new
approach for treatment of cancers. P53 plays a vital role in tumor suppression and surveillance. Therefore, we
hypothesize that a recombinant NDV expressing P53 would be an ideal agent for the hepatoma therapy.
Results: In the essay, the human P53 gene was incorporated into the genome of a lentogenic strain (named rNDV-P53),
which did not affect viral replication kinetics and magnitude in HepG2 cells. Compared to the vehicle virus, rNDV-P53
increased cell growth suppressor ratio and early apoptosis by 2 folds, and decreased the mitochondrial membrane
potential in HepG2 cells. In vivo studies, treatment with rNDV-P53 reduced tumor volume of tumor-bearing mice by more
than 4 folds, tumor weight by more than 5 folds comparing with rNDV. The 120-day survival rate of rNDV-P53-treated
mice was 75 %, survival rate of rNDV-treated mice was 12.5 %. TUNEL analysis showed a significant increase in the
apoptosis rate in the tumor tissues of rNDV-P53-treated mice than that of rNDV-treated mice. Moreover, serum
chemistries revealed an insignificant change of blood urea nitrogen (BUN), creatinine levels, alanine aminotransferase
(ALT) and aspartate transaminase (AST) in rNDV-P53-treated group compared to normal mice, suggesting treatment with
the recombinant virus was not toxic.
Conclusion: rNDV-P53 is a potent candidate for carcinoma therapy especially for hepatocarcinoma.
Keywords: Recombinant NDV, P53, Gene therapy, Anti-tumor
Background
Newcastle disease virus (NDV) is a single-strand non-
segmented negative-sense RNA virus of the paramyxoviri-
dae family [1]. Causing severe infection to multiple avian
species, but is not pathogenic to humans. The genome
containing 15186 nucleotides encodes six genes, including
the nucleocapsid protein (NP), phosphoprotein (P), matrix
protein (M), fusion protein (F), hemagglutinin neuramin-
idase (HN) and RNA-dependent RNA polymerase (L) [2,
3]. NDV was proposed as a promising anticancer agent
[4–7], it is prone to replicate in human tumor cells and
cause oncolytic effects but not in normal cells [8–10],
which is a superior characteristic as a therapeutic agent
for cancers compared with the other oncolytic virus. The
anticancer potency of NDV depends on the ability to in-
duce apoptosis in infected cancer cells [11–13]. However,
previous studies have demonstrated that NDV induces
apoptosis in tumor cells independent of the function of
the P53 [14, 15].
The P53 tumor suppressor plays various roles in cell-
cycle control, apoptosis, senescence, DNA repair and
modulating metabolic processes [16–20]. As a transcrip-
tion factor, P53 can regulate several proteins, such as
pro-apoptotic Bcl-2, caspases, death receptors and so on.
With the expression of these genes, cell death was in-
duced by apoptosis [21, 22]. Meanwhile, the tumor sup-
pressor P53 is inactivated by mutations, which can be
found in about 50 % of human cancers [23, 24]. It has
been proposed that the increased survival of tumor cells
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lacking functional P53 is due to the decreased ability of
these cells to undergo apoptosis [25]. Briefly, the expres-
sion of wt-P53 gene can inhibit tumorigenesis. It is not
surprising that restoring wild-type P53 activity has been
used as a cancer gene therapy in both laboratory studies
and clinical trials [26–29].
In the present study, we generated a recombinant
NDV (named rNDV-P53) and evaluated its antitumor ef-
ficacy in vitro and in vivo tests. We showed that the
virus possesses a significant oncolytic activity against
hepatoma cell line HepG2 and is an effective oncolytic
agent in a H22 tumor mouse model. In a conclusion, we
conclude that recombinant NDV expressing P53 is a
promising agent for cancer therapy.
Methods
Cell culture
The human hepatoma cell line of HepG2, Hep3B and
the mice hepatoma cell line of H22 were supplied by
northeast agricultural university biological pharmaceut-
ical teaching and research section. The baby hamster
kidney cell line of BHK21 was a generous gift from Dr.
B.Moss. HepG2 and BHK21 cells were cultured in
DMEM containing 10 % new-born calf serum (NCS)
and 1 % penicillin/streptomycin. All cell lines were
maintained at 37 °C in a 5 % CO2 atmosphere and 95 %
humidity.
Recombinant Newcastle disease virus
The total RNA of human peripheral blood leukocytes
was prepared by using Trizol and then was transcribed
into cDNA. The P53 gene was amplified by PCR using
the human peripheral blood leukocytes cDNA as tem-
plate and the following primers: sense 5′-ATGGAG
GAGCCGCAG-3′and antisense 5′-TCAGTCTGAGTC
AGGCCCTT-3′. The PCR product was purified by 1 %
agarose gel electrophoresis and inserted into HpaI-MluI
fragment of clone30 plasmid. The nucleotide sequence
was identified by sequence analysis and compared with
the reported P53 gene [GenBank: 82395019]. And then
the recombinant plasmid was transiently cotransfected
with helper plasmids encoding viral NP, P and L into
BHK21 cells stably expressing T7 RNA polymerase using
lipofectamine 2000. The virus was rescued and amplified
by inoculation of the supernatant from the transfected
cells into the allantoic cavity of specific-pathogen free
chicken embryos.
Determination of virus growth
Virus growth was determined in HepG2 cells culture.
HepG2 cells in 6-well plates were infected with recom-
binant virus at 37 °C in DMEM supplemented with 10 %
new-born calf serum and 1 % penicillin/streptomycin in
a 5 % CO2 atmosphere. Cells with supernatants were
frozen at the time indicated i.e. 24, 48, 72, 96 h post-
infection. After repeated freezing and thawing 3 times,
the cells with supernatants were collected. The concen-
tration of virus was determined by end-point titration
on chicken embryo fibroblast cells and was expressed as
mean log10 50 % tissue culture infective dose (TCID50)
per ml. Finally, according to the virus titer in different
time a growth curve was drawn.
Determination of exogenous P53 protein expression by
Western blotting
HepG2 and Hep3B cells (5 × 106 cells) were infected
with rNDV-P53 at 1 MOI. After 24 h incubation, cells
were collected and washed twice with cold PBS by cen-
trifugation at 500 × g for 5 min at 4 °C. The pellet was
resuspended in lysis buffer supplemented with proteases
inhibitor and the supernatant was stored at -20 °C. For
western blotting analysis, samples were separated by
10 % sodium dodecylsulfate-poly acrylamide gel electro-
phoresis (SDS-PAGE), and transferred to a nitrocellulose
membrane. The blot was visualized by chemilumines-
cence and autoradiography using X-ray film. Mouse
anti- human P53 polyclonal antibody (DO-1) was ob-
tained from Santa Cruz Biotechnology Inc., CA, USA. A
protein marker (New England Biolabs, Beverly, MA,
USA) was run for each gel to identify P53.
Cell viability assay
A short-term microculture tetrazolium (MTT) assay was
used to quantify cell viability. Approximately 2 × 104
HepG2 cells were plated into 96-well plates in complete
medium and allowed to attach for 24 h. Subsequently,
the cells infected with rNDV-P53, rNDV at 0.01 MOI,
0.1 MOI, 1 MOI, and 10 MOI in triplicate. After 48 h of
incubation, 20 μl MTT solutions (5 mg/ml in sterile
phosphate-buffered saline) were added to the cell. 4 h
later, the MTT solution in the wells was discarded, then
150 μl dimethyl sulfoxide (DMSO) was added. The
absorption at 490 nm (OD490) was measured on a mi-
croplate reader. The cell viability was converted and
expressed as the percentage of the control. The cells
without any treatment were used as negative control.
Inhibition rate % ¼ control group OD ‐ treatment group ODð Þ =
control group OD 100%
Annexin V –FITC and PI binding assay
Approximately 2 × 104 HepG2 cells were plated into 6-
well plates in complete medium and allowed to attach
for 24 h. Subsequently, the cell infected with rNDV-P53,
rNDV at 0.1 MOI, 1 MOI, and 10 MOI in triplicate.
After 48 h of incubation, cells (0.5 ~ 1x106) were
digested with 0.25 % trypsin, then resuspended by
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adding 200 μl Binding Buffer. Then the cells were incu-
bated away from light with 5 μl Annexin V labelled
FITC 30 min at room temperature. At last, after being
mixed with 5 μl PI and 300 μl Binding Buffer and
reacted 5 ~ 15 min away from light, the cells were quan-
titatively detected by flow cytometry (usually within 1 h),
at the same time a tube cells without AnnexinV-FITC
and PI served as a negative control. Cells were analyzed
in a flow cytometry using FL1 (530 nm) bandpass filters
of FACS Calibur (Bectom Dickinson, USA), and data
were analyzed by the CellQuest software (BD, USA).
Measurement of mitochondrial membrane potential
Changes in mitochondrial transmembrane potential
(ΔΨM) were measured by using 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetra-ethylbenzimidazolylcarbocyanine iodide
(JC-1) as a probe. HepG2 cells were plated in six-well
plates at 1 × 105 cells/well and infected by the recombin-
ant virus rNDV-P53 and rNDV at 1 MOI. After 12 or
24 h of incubation, cells were digested with 0.25 % tryp-
sin, then resuspended in 1 ml DMEM containing JC-1
(20 μg/ml). Then cells were incubated for 30 min in dark
at room temperature. Cells were washed twice with PBS,
re-suspended in 0.5 ml PBS, and immediately analyzed
in a flow cytometry using FL1 (590 nm) band pass filters
of FACS Calibur (Bectom Dickinson, USA).
In vivo evaluation of tumor growth
All procedures involving animals followed the guide-
lines issued by National Institute of Health and the
Institutional Animal Care and Use Committee of
Northeast Agriculture University (approval number:
SCXK-2011-0004).
Six-week-old male ICR mice (with a mean weight of
18 g) were housed in a pathogen-free environment and
implanted subcutaneously with 2 × 106 H22 cells into
the right groin. When the tumor size reached about
50 mm3, the animals were randomly divided into three
groups. Then the tumor-bearing mice were intratumoral
injection inoculated with a single injection of 1 × 107 pfu
of rNDV-P53 or rNDV in a 200 μl volume and 200 μl of
PBS were injected instead of the virus, which repre-
sented as control. Tumor growth was observed every
2 days for 18 days by measuring the two dimensional
longest axis (L) and shortest axis (W) with a caliper. The
tumor volume was calculated by using the following for-
mula: volume in mm3 = 4/3 × π × (L/2 × W/2 × W/2).
According to the institutional protocols, the mice were
euthanized when the tumors reached 18 mm in diam-
eter. On day 18, all mice from the control group and 6
mice from each treatment group were sacrificed and
their tumors were excised. The tumors were weighted
and immersed in 4 % paraformaldehyde. Then all sec-
tions were cut at 4 mm thick from buffered formalin-
fixed, paraffin-embedded tumors. After deparaffinization,
sections were stained with haematoxylin/eosin (H&E)
and prepared for TUNEL assay (terminal deosynucleo-
tidy transferase-mediated dUTP nick and labeling assay).
In addition, serum was prepared from whole blood for
determination of serum concentrations of AST, ALT,
BUN, and creatinine. The remaining mice in each treat-
ment group were observed for 120 days with measure-
ment of tumor volume. This was disease-free 120-day
survival rate.
Statistical analysis
All the data were obtained from at least three inde-
pendent experiments. The data are expressed as mean
values ± SD and were compared using Student′s t test.
Statistical significance was defined as a P value < 0.05.
Results
Recovery of the recombinant virus rNDV-P53
The human wild-type P53 gene was inserted into the
newly created Hpa I and Mlu I sites between the F and
HN genes of the NDV genome (Fig. 1). Then we gener-
ated the recombinant virus rNDV-P53. The incorporated
plasmid was transfected into BHK-21 cells. Then the
supernatant of the transfected monolayers was injected
into 10-day-old SPF embryonated chicken eggs. After
3 days, the allantoic fluid was harvested and analyzed in
a HA test. The high titers of rNDV-P53 suggested the
successful generation of the recombinant NDV virus.
Growth and exogenous P53 protein expression of the
recombinant virus rNDV-P53
In order to verify the recombinant virus rNDV-P53 re-
mains stable proliferation in tumor cells, HepG2 cells
were infected with rNDV-P53 at MOI of 1 and the
supernatant of them was harvested at different time
points. Then the viral titers in the supernatants were de-
termined in triplicate. As shown in Fig. 2a, compared
with the parental virus, the recombinant virus rNDV-
P53 has no any distinctions in the kinetics and magni-
tude of replication while the production of rNDV-P53
was slightly delayed. To investigate the expression of
Fig. 1 Construction of rNDV-P53. Diagram showing insertion of
the P53 gene into the NDV genome at the position between
the F and HN genes
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P53 protein, HepG2 and Hep3B cells were treated with
rNDV-P53 at MOI of 1. Western blotting analysis
(Fig. 2b) showed that the P53 expression increased in
the tumor cells infected with rNDV-P53.
Recombinant virus rNDV-P53 suppresses tumor cell
growth in vitro
The direct cytotoxic activity of the recombinant virus
rNDV-P53 was tested in HepG2 tumor cells in this
study. As shown in Fig. 3a, rNDV-P53 induced cell death
in a dose-dependent manner during 24 hour′s treatment
in HepG2 cells. When the cells were infected with
rNDV-P53 or rNDV of 10 MOI for 24 h, the viability of
HepG2 cells dramatically decreased to 45.03 % ± 3.6 %,
73.67 % ± 2.51 %, respectively. In the meanwhile, the cell
growth suppressor ratio induced by rNDV-P53 is up to
1.7 times of rNDV (MOI = 1). Collectively, these data
demonstrate that the recombinant virus rNDV-P53 is
superior to parent virus in suppressing the growth of
HepG2 cells.
To determine the sensitivity of tumor cell to recom-
binant virus-induced apoptosis, HepG2 cells were
treated with recombinant virus rNDV-P53 for 24 h, and
the percent of apoptotic cells was determined by
Annexin V-FITC/PI assay. Apoptosis assay showed that
after virus infection the tumor cell death by apoptosis
was occurred markedly. The results showed that apop-
tosis percentages of rNDV group and rNDV-P53 were
10.4 % and 21.1 % respectively, which indicated that
virus rNDV-P53 were more effective in inducing apop-
tosis in the HepG2 cells (Fig. 3b). In line with the obser-
vation of cell death, rNDV-P53 induced apoptosis in a
dose-dependent manner.
To explore the molecular mechanisms by which
virus induced cell death, the mitochondrial membrane
potential of HepG2 cells infected with virus was
assayed by using the fluorescent dye JC-1. JC-1 accu-
mulates in mitochondria as aggregates, resulting in
red fluorescence in non-apoptotic cells. The mono-
meric form, which fluoresces green, is found in
apoptotic cells. As shown in Fig. 3c, the green fluor-
escence of JC-1 increased in HepG2 cells treated with
virus over the time course. Both rNDV and rNDV-
P53 reduced the mitochondrial membrane potential
compared with the PBS group, but the effect of rNDV
was not as potent as rNDV-P53. These results indi-
cate that the recombinant virus can effectively reduce
the mitochondrial membrane potential, which is the
key in cell apoptosis.
These data suggest that the insertion of P53 gene
improved the ability of NDV inducing tumor cell
apoptosis.
Fig. 2 Growth curve of the recombinant virus and Exogenous P53 protein expression. a The virus titers in the supernatant of different time
points were assessed by plating tenfold dilution on DF-1 cells and were shown as log10TCID50/ml. b The β-actin was used as control
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Fig. 3 (See legend on next page.)
An et al. Journal of Biomedical Science  (2016) 23:55 Page 5 of 10
The recombinant virus rNDV-P53 suppresses tumor
growth in mice
The mice H22 hepatocellular carcinoma model was
employed in our study for examining the tumor sup-
pressing efficacy of the recombinant virus rNDV-P53 in
vivo. When the tumor size reached about 50 mm3, the
animals were divided into three groups. The mice were
intratumorally treated with 1 × 107 pfu of rNDV, rNDV-
P53 or PBS every other day for nine injections. The
tumor growth was observed by measuring the tumor
size every other day for a total of 18 days. After nine in-
jections, all animals in the PBS group were sacrificed
(See figure on previous page.)
Fig. 3 The recombinant virus rNDV-P53 induces cell death by apoptosis in human tumor cells HepG2. a Cytotoxicity of rNDV-P53 in tumor cells.
HepG2 cell were infected with rNDV or rNDV-P53 virus for 24 h. Cell viability was determined by MTT assays (mean ± SD). Replicates were aver-
aged, and the error bars represent the SD of three independent experiments. b The cells were infected with the rNDV or rNDV-P53 in different
dosages. Cell apoptosis was detected by Annexin V-FITC/PI Apoptosis Detection Kit according to the manufacturer′s instructions and followed by
flow cytometry. c After 12 h or 24 h of virus infection, HepG2 cells were stained with JC-1 and analyzed by flow cytometry
Fig. 4 The recombinant virus rNDV-P53 suppresses the growth of H22 xenografts in mice. A xenograft H22 animal model was established in mice.
When the tumor size reached to about 50 mm3 (about 7 days post-inoculation), the tumors were injected with 1 × 107 pfu of rNDV or rNDV-P53
virus (day 0). The PBS was used as control. The injections were repeated every 2 days during experimental period. Mice were killed when the
tumors reached 18 mm in length. On day 18, all mice from the control group and 6 mice from each treatment group were sacrificed and their
tumors were excised. The remaining 8 mice in each treatment group were observed for 120 days with measurement of tumor volume. a The
tumor growth was observed by measuring the tumor size every 2 days for 18 days. b The weight of the excised tumors of different groups. c The
excised tumors of different groups. d Before necropsy, the tumor in the right groin of different groups mice. e The percent survival of tumor-bearing
mice treated with PBS, rNDV, and rNDV-P53 in the 120 days (**p < 0.01; *p < 0.05)
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due to excessive tumor burden. The average tumor size
for the PBS-control group was 5702.93 ± 540.25 mm3,
while 666.96 ± 222.62 mm3 noted for the rNDV-P53
group. For the group treated with rNDV, the average
tumor sizes were 2785.45 ± 254.30 mm3 (Fig. 4a). More-
over, the average tumor weight of PBS-control group
was 6.14 ± 0.81 g. For the group treated with rNDV and
rNDV-P53, the average tumor weight was 3.52 ± 0.33 g
and 0.64 ± 0.24 g, respectively (Fig. 4b). During necropsy,
tumors excised from the control group were fairly large
in size and tumors isolated from the rNDV-P53 group
were generally small (Fig. 4c, d). Taken together, these
data demonstrate that the recombinant virus rNDV-P53
have a very significant effect in tumor inhibition com-
paring with rNDV.
In this study, the survival time course of the tumor-
bearing mice was also recorded. Over the 120 days
(Fig. 4e), remaining 7/8 mice in the rNDV group devel-
oped significant size and needed to be sacrificed. While
only 2/8 mice in the rNDV-P53 group developed tumors
that required to be sacrificed. The remaining mice in
each group either completely cleared or had persistent
pigmented focus that did not change in size. The overall
survival of the mice in the long-term study was 0/8 for
control group, 6/8 for rNDV-P53 group and 1/8 for
rNDV group.
As shown in Fig. 5a, H&E staining tumor sections
show tumors derived from rNDV-P53 demonstrated a
stronger suppression to cellar viability than rNDV and
PBS group. Then we evaluated the cytotoxic effect of the
recombinant virus rNDV-P53 on tumor issue by TUNEL
assay. Compared with a control group, we found a sig-
nificant increase in the apoptosis rate of the rNDV-P53
group (Fig. 5b). These data indicate that rNDV-P53 in-
duces apoptosis, consequently inhibiting the growth of
tumor tissue.
In order to assess the safety and reliability of the re-
combinant virus administration in vivo, a toxicity study
was performed in mice. After ten injections, the blood of
mice injected with PBS and rNDV-P53 was collected.
Serum chemistries revealed insignificant changes in
BUN, creatinine levels, AST and ALT (Fig. 6). According
to the results, we concluded the systemic effects of the
rNDV-P53 treatment at mice were similar to the PBS
treatment. Briefly, the recombinant virus is safe.
Discussion
Newcastle disease virus (NDV) has a number of advan-
tages as an attractive candidate for viral vector for can-
cer therapy. First of all, NDV can selectively replicate in
tumor cells and cause lysis of cancerous cells while spar-
ing normal cells [30–32]. Secondly, NDV mediates anti-
tumor effects by inducing apoptosis in cancer cells.
Multiple subsequent studies confirmed that the apop-
tosis plays a dominant role in NDV-induced cell death,
and the apoptosis inducing effect does not depend on
the presence of functional P53 protein in the infected
tumor cells [33–36]. Lastly, NDV is a bird virus without
pathogenicity in humans, in extreme cases of virus
infections, humans only have mild conjunctivitis,
laryngitis and flu-like symptoms. In addition, as a viral
vector, NDV does not integrate into the human genome
[37–40]. These facts contribute to its safety.
The tumor suppressor P53 is a stress-activate tran-
scription factor that regulates several genes with a broad
range of functions including DNA repair, apoptosis, cell
cycle arrest, metabolism and senescence [20]. In ap-
proximately 50 % of human tumors, P53 gene is mutated
and losses its function [41]. It is the reason why P53 has
emerged as a promising target of gene therapy tech-
niques [42]. P53 gene therapy is aim to prevent tumor
formation or lead to tumor regression by restoring the
activity of P53. So a strategy has been provided to elim-
inate tumor cells and induce apoptosis by reintroducing
wild-type P53 into tumor cells. In the early 1990s, scien-
tists delivered P53 into tumor cells to induce apoptosis
and growth inhibition [43]. Later studies demonstrated
the effectiveness of P53 gene therapy, for instance the
recombinant adenovirus expressing human P53 achieved
good curative effect on malignant liver cancer, gastric
cancer, bladder cancer and cervical cancer [44–47].
Due to the superiority of Newcastle disease virus as a
vector for cancer therapy and the effectiveness of P53
gene therapy, we constructed the recombinant virus
rNDV-P53 using reverse genetics. As we expected, the
kinetics and magnitude of replication of the recombinant
NDV didn′t have a significant change, the P53 expres-
sion increased in the tumor cells infected with rNDV-
P53. In addition, we have shown that compared with the
vehicle virus, rNDV-P53 significantly inhibited HepG2
Fig. 5 Representative sections of H&E-stained mouse tumors and
TUNEL-stained mouse tumors dissected on day 18. a Mouse tumor by
H&E-stained. b Apoptotic cells in the tumor tissues were visualized by
TUNEL assay. Brown colored cells represent apoptotic cells. PBS was
used as control (magnification, 400X)
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cells growth. We hypothesized that the ability of rNDV-
P53 in inducing cell death was enhanced by the inserted
gene P53. To confirm this conjecture, we tested this hy-
pothesis in cancer cell lines HepG2. When the cells were
infected with virus of 10 MOI for 24 h, the early apop-
tosis rate induced by rNDV-P53 was 21.1 % and the ve-
hicle virus was 10.4 %. Apoptosis analysis showed that
rNDV-P53 strengthens pro-apoptotic activity of virus. It
is consistent with the previously report that restoring
wild-type P53 activity leads to apoptosis in cancer cells
[48]. Previous investigation suggests that the apoptosis
induced by P53 is accompanied by the decrease of mito-
chondrial membrane potential [49]. Using the fluores-
cent dye JC-1, we observed a further loss of membrane
potential causing by the rNDV-P53 compared with its
parental stain (Fig. 3c). Based on the encouraging data in
vitro, we investigated the therapeutic efficacy of rNDV-
P53 in H22-bearing mice. At the end of the experiment,
the tumor weights and volumes significantly decreased
in mice treated with rNDV-P53 compared with those
treated with rNDV or PBS. The average tumor volume
in rNDV-P53 group was 666 mm3 verses over
2000 mm3 in rNDV or PBS group. The average tumor
weight in rNDV-P53 group was 0.64 ± 0.24 g verses 3.52
± 0.33 g in rNDV group and 6.14 ± 0.81 g in PBS group,
respectively. These results indicate that rNDV-P53 can
effectively inhibit tumor growth. In addition, TUNEL ex-
perimental results showed that the rNDV-P53 has a
stronger ability to induce apoptosis in tumor tissue than
rNDV. rNDV-P53 significantly increased the survival
rate of mouse liver cancer model. At the end of the
120 days survival experiment, the overall survival of the
untreated model mice was 0/8 verse 6/8 for the rNDV-
P53 group and 1/8 for the rNDV group. In order to as-
sess potential toxicities associated with recombinant
virus in vivo, a toxicity study was performed. AST and
ALT are the important indexes in evaluating liver func-
tion, the blood urea nitrogen and creatinine are the im-
portant indexes in evaluating renal function. We have
detected the BUN, creatinine, AST, and ALT. Results
showed that these parameters were in the normal range,
indicating that rNDV-P53 is relatively safe for cancer
therapy.
Conclusion
In conclusion, we demonstrate a promising oncolytic
agent rNDV-P53 consisting of an ideal vector and a
suppressor gene P53. Our studies demonstrated that
rNDV-P53 is efficacious in suppressing hepatocellular
carcinoma model and has the potency to cure the mice
completely. Thereby we offered a promising antitumor
agent for hepatoma.
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